E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Hematology Highlights: News from the 50th Annual Hematology Meeting


Register Now

Solving the Challenges of Hematalogic Malignancies through Translational Research

Friday, December 5, 2008

San Francisco, California

The Moscone Center: Exhibit Level Room 104 Symposium

Who Should Attend

This educational activity is specifically designed for hematologists, oncologists, and other health care practitioners involved and/or interested in the care of persons with hematologic malignancies.

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 2.5 of AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives

After successful completion of this program, the participant will be able to:

  • Discuss the role of epigenetics in cancer
  • Describe approved targeted histone deacetylase therapies for the treatment of hematologic malignancies
  • Evaluate emerging histone deacetylase inhibitor efficacy and toxicity profiles
  • Discuss approved targeted tyrosine kinase therapies for the treatment of hematologic malignancies
  • Evaluate emerging tyrosine kinase inhibitor efficacy and toxicity profiles
  • Improve therapeutic outcomes with currently available and investigational treatment options for patients with chronic myeloid leukemia

Francis J. Giles, MB, MD, FRCPI, FRC
Path The Cancer Center at the University of Texas
San Antonio, Texas, United States

Jonathan Licht, MD
Northwestern University
Chicago, Illinois, United States

Ruben Mesa, MD
Mayo Clinic
Rochester, Minnesota, United States

Owen O'Connor, MD, PhD
Columbia University
New York, New York, United States

H. Miles Prince, MD, MRACMA, FRACP, FRCPA
Peter MacCallum Cancer Center
Melbourne, Australia

 

Friday, December 5, 2008

12:30 pm
Lunch: Exhibit Level Room 102/103

1:30 pm
Adjourn to symposium:
Exhibit Level Room 104

1:45 pm
Epigenetics and cancer: A causal relationship
Jonathan Licht, MD

2:05 pm
Q&A

2:10 pm
Targeting histone deacetylase to reverse the malignant phenotype
Owen O’Connor, MD, PhD

2:30 pm
Q&A

2:35 pm
Novel inhibitors of histone deacetylase and their role in cancer therapy
H. Miles Prince, MD, MRACMA, FRACP, FRCPA

2:55 pm
Q&A

3:00 pm
Targeting tyrosine kinases in hematologic malignancies: Selecting targets and designing therapeutic agents
Francis J. Giles, MB, MD, FRCPI, FRCPath

3:20 pm Q&A

3:25 pm
Novel inhibitors of tyrosine kinases and their expanding roles in hematologic malignancies
Ruben Mesa, MD

3:45 pm
Q&A

3:50 pm
Managing the increasing therapeutic options available for chronic myeloid leukemia
Francis J. Giles, MB, MD, FRCPI, FRCPath

4:10 pm
Q&A

4:15 pm
Adjourn

 

This Satellite is complimentary to registered ASH attendees. Pre-registration is currently available.

ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

 

This Satellite Symposium is made possible by an educational grant from:
Novartis